Abstract
Introduction and Aim: Vaccines from various manufacturers have shown their efficacy against COVID-19 globally. In this study, the aim was to evaluate the immune response in subjects after the second vaccination with inactivated SARS-CoV-2 virus at Mamami Hospital located in a rural area in Indonesia. Materials and Methods: The study employed a cross-sectional research design. The research took place at Mamami Hospital, Kupang City, East Nusa Tenggara, Indonesia, from April 5 to August 8, 2021. The research comprised a total of 30 health workers who served as the participants in this study. Results: Immunoserology results show that 1 respondent was non-reactive and 2 had antibody results < 10. There were 7 respondents with antibody results > 10 - 40. Serological antibodies > 40 - 80 were found in 3 respondents. Serological antibodies > 80 - 120 were not found. Serological antibodies > 120 - 160 were found in 3 respondents. One respondent had serological antibodies ranging from 160 to 200, while 13 respondents had antibodies ranging from 200 to 400. Conclusion: In the present study, inactivated SARS COV-2 virus vaccine significantly contributed to the acquisition of anti-SARS-CoV-2S antibodies of 30 health workers.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
